First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial [0.03%]
奥美替尼联合阿帕替尼对比奥美替尼一线治疗EGFR突变型非小细胞肺癌患者：一项随机、多中心Ⅱ期临床试验
Fan Zhang,Zhendong Zheng,Hongmei Zhang et al.
Fan Zhang et al.
Inactivating vascular endothelial growth factor receptor (VEGFR) may improve the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). The ATTENTION study (p...
Employing epigenetic protein degradation techniques to block CCL5-mediated photodynamic therapy via a programmed delivery platform [0.03%]
利用表观遗传学蛋白质降解技术通过程序化递送平台阻断CCL5介导的光动力疗法
Tingting Yang,Yuzhu Hu,Anjie Guo et al.
Tingting Yang et al.
Despite the significant potential of photodynamic therapy (PDT) in cancer treatment, further refinement is needed to address challenges such as poor tumor-specific accumulation of photosensitizers and the development of therapeutic resistan...
CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies [0.03%]
CXCR4修饰通过提高B细胞恶性肿瘤的肿瘤追踪和骨髓归巢增强CAR-T疗效
Pei Shu,Fuchun Guo,Diyuan Qin et al.
Pei Shu et al.
Hematological malignancies of B cell origin are characterized by frequent expression of CXCR4. The CXCR4-CXCL12 axis facilitates the in vivo dissemination of B cell lymphoma and multiple myeloma (MM). It is also a pivotal regulator in the m...
Deciphering the regulatory landscape of enhancer RNAs in health and disease [0.03%]
解析增强子RNA在健康与疾病中的调控景观
Qian Wang,Peter Ten Dijke,Chuannan Fan
Qian Wang
Enhancers are distal cis-regulatory elements that orchestrate spatiotemporal gene expression patterns in response to developmental cues and environmental stimuli. Genetic and epigenetic alterations in enhancers are associated with the initi...
Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications [0.03%]
针对癌症代谢-表观遗传-免疫轴的分子机制和治疗意义
Xing Wang,Xiyuan Luo,Ruiling Xiao et al.
Xing Wang et al.
Cancer cells orchestrate a highly dynamic and interconnected network spanning metabolic, epigenetic, and immune mechanisms to drive adaptive plasticity and continuous development. This review synthesizes emerging insights into the coevoluti...
Chunmei Cai,Guohua Ni,Lei Chen et al.
Chunmei Cai et al.
At high altitudes, which typically exceed 2500 m, approximately 80 million people reside permanently, with over a million visitors annually. The primary effect of high altitude is hypobaric hypoxia, which leads to decreased oxygen availabil...
Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma [0.03%]
奥西替尼通过抑制MYLK4介导的CDKAL1磷酸化来抑制横纹肌肉瘤干细胞样特性及化疗耐药性
Takuto Itano,Rongsheng Huang,Toshifumi Ozaki et al.
Takuto Itano et al.
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study [0.03%]
仑伐替尼联合经动脉化疗栓塞和PD-1抑制剂作为不可切除的中晚期肝细胞癌新辅助/转化治疗的II期临床研究及探索性生物标志物研究
Xiaoyun Zhang,Haozheng Cai,Wei Peng et al.
Xiaoyun Zhang et al.
Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospective phase 2 multicenter trial (NCT0499785...
Multiomics Mendelian randomization identifies serpin family G member 1 as a chronic obstructive pulmonary disease modulator [0.03%]
多组学孟德尔随机化鉴定出蛋白酶抑制剂家族G成员1是慢性阻塞性肺疾病的调节因子
Erkang Yi,Jieda Cui,Hairong Wang et al.
Erkang Yi et al.
Chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, lacks effective disease-modifying therapies, partly because of complex gene-environment interactions and extensive missing heritability. Here, we appl...
May Bakr,Mohamed Salama
May Bakr